Genmab — August 2017
-
Samt til alle jer andre.

-
Vi har plads til flere spørgsmål.

-
What in Jan’s view the reason for the very diversified perception of the Darzalex case by the Financial analysts? (The latest Bloomberg financial analysts overview, indicate more skepticism)
-
Mangler et "is" - men du er skarp Helge så jeg er sikker på du har set det

-
Her for at lære...Du skal stille spørgsmålet i Q&A chatten.

-
Tilmelding og instruktion her. http://www.proinvestor.com/index.php?p=q-and-a&groupid=83
-
Vi har fået svar omkring ekskursionen. Vi bliver kontaktet efter indflytning sidst på året.
-
Har kigget lidt på de tilgængelige tal og regnet mig frem til et Revenue for H1 på 850 mil. dkr mod 524 dkr for H1 2016 en stigning på ca. 62 %. Så hvis der skulle komme en eller anden form for op præcisering, så vil bukserne blive trukket af marked, incl. undertegnede.
-
https://clinicaltrials.gov/ct2/show/NCT03242889 - A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind